Olympus to develop Kaken's growth factor in the US and Europe
This article was originally published in Scrip
Kaken has licensed its human basic fibroblast growth factor (bFGF) product trafermin to the diversified Japanese group Olympus, for development, manufacture and marketing in wound healing applications in North America and Europe.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.